A carregar...
Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis
BACKGROUND AND AIMS: There are limited data on the most cost-effective sequencing of biologics for ulcerative colitis [UC]. METHODS: We used Markov modelling to identify the most cost-effective position for vedolizumab among biologics for steroid-dependent UC, with a base-case of a 35-year-old male....
Na minha lista:
| Publicado no: | J Crohns Colitis |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7303595/ https://ncbi.nlm.nih.gov/pubmed/31901085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjz212 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|